Nothing Special   »   [go: up one dir, main page]

van der Noord et al., 2019 - Google Patents

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

van der Noord et al., 2019

View HTML
Document ID
2933897476204619576
Author
van der Noord V
McLaughlin R
Smid M
Foekens J
Martens J
Zhang Y
Van de Water B
Publication year
Publication venue
Scientific Reports

External Links

Snippet

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies. Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Similar Documents

Publication Publication Date Title
Farrell et al. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
Inoue-Yamauchi et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Kitagawa et al. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality
van der Noord et al. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
Radhakrishnan et al. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
Hotta et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review
Logsdon et al. Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival
Daniel et al. Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling
Wu et al. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
Zhang et al. High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer
Hempel et al. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients
Smida et al. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Way et al. A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma
Zhang et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy
Malvi et al. LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
Willis-Owen et al. Y disruption, autosomal hypomethylation and poor male lung cancer survival
Wolf et al. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
Harada et al. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
Sabnis et al. A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma
Zhao et al. GNG2 acts as a tumor suppressor in breast cancer through stimulating MRAS signaling
Masoumi et al. Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
Gray et al. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
He et al. The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer
Chu et al. Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
Migliaccio et al. PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer